Amgen Canada Launches Adalimumab Biosimilar
By EsqSocial Corporation 11/05/21
On May 4, 2021, Amgen Canada announced the launch of their adalimumab biosimilar AMGEVITA (reference drug HUMIRA) for the treatment of 11 chronic inflammatory conditions. AMGEVITA is available as a prefilled syringe and a prefilled pen (SureClick® autoinjector) with a range of pack sizes to support dosing according to the approved dosage recommendations in each indication....
By: Goodwin